BRAIN STIMULATION: Basic, Translational, and Clinical Research in Neuromodulation
Volume 2, Issue 1 , Pages 41-49, January 2009

A pilot study of the teratogenicity of vagus nerve stimulation in a rabbit model

  • Ingela Danielsson, MD, PhD

      Affiliations

    • Cyberonics, Inc, Houston, Texas
    • Corresponding Author InformationCorrespondence: Dr. Ingela Danielsson, 100 Cyberonics Blvd., Houston, TX 77058.
  • ,
  • Laurence Lister, BS

      Affiliations

    • Toxikon, Inc, Bedford, Massachusetts

Received 26 October 2007; received in revised form 11 June 2008; accepted 12 June 2008. published online 10 October 2008.

Background

Vagus nerve stimulation (VNS) is approved for the adjunctive treatment of both refractory epilepsy and treatment-resistant depression. This study assessed the effect of VNS on fertility, teratogenicity, and neonatal morbidity in rabbits.

Methods

Ten female New Zealand white rabbits (test animals) were implanted with the VNS device. Ten additional female rabbits (surgical controls) received nonfunctional devices. Four additional female rabbits served as untreated controls and 10 male rabbits served for siring purposes. Test rabbits received VNS at 1 mA, 30 Hz, 500 microseconds, 30 seconds ON, 5 minutes OFF. Rabbits mated and were randomly assigned into 2 groups: those killed on day 28 and those proceeding through parturition. Groups were compared by using a 1-way analysis of variance with a Newman-Keuls Multiple Comparison post-hoc test. Differences between control and test animals were considered statistically significant if P ≤ .05.

Results

No statistically significant differences were noted for weight, matings required for successful copulation, food or water consumption, hematology, clinical chemistry, organ weights, uterine contents, kit weights and survival, or clinical observations. No changes or abnormalities could be attributed to the VNS device at necropsy or histopathologic assessment. No skeletal or soft tissue abnormalities were noted in any of the fetuses.

Conclusions

In this very small sample of rabbits treated with VNS, we failed to find any conclusive teratogenic effects of VNS. The sample was too small, however, to support definitive conclusions regarding this issue. Brain stimulation devices in general and VNS in particular are potentially attractive in managing brain disorders such as epilepsy and depression during pregnancy and lactation as they do not have the systemic effects characteristic of medications and do not directly affect the fetus. Further studies are needed to address this issue.

Keywords: vagus nerve stimulation, teratogenicity, pregnancy, birth defects, VNS

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The results of the teratogenicity study were presented in poster form at the 57th meeting of the American Epilepsy Society, December 5-10, 2003, in Boston, Massachusetts, Harden, CL (Comprehensive Epilepsy Center, Weill Medical College of Cornell University, New York, NY) High-dose vagus nerve stimulation does not cause teratogenicity in animals.

 Cyberonics, Inc, manufacturer of the VNS Therapy System, compensated Toxikon, Corporation of Bedford, Massachusetts, for performing this reproductive and developmental toxicity screening test. Mr. Laurence Lister, an author of this article, is an employee of Toxikon Corporation, which was contracted to perform the Reproductive Screening study; Mr. Lister received no direct compensation from Cyberonics for directing the study. Ingela Danielsson, MD, PhD, an author of this article, is a stockholder of Cyberonics, Inc.

PII: S1935-861X(08)00043-0

doi:10.1016/j.brs.2008.06.008

BRAIN STIMULATION: Basic, Translational, and Clinical Research in Neuromodulation
Volume 2, Issue 1 , Pages 41-49, January 2009